Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Tocagen Inc (TOCA) today and set a price target of $10. The company’s shares closed yesterday at $5.08, close to its 52-week low of $4.13.
According to TipRanks.com, Livshits is a 4-star analyst with an average return of 14.4% and a 54.2% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Logicbio Therapeutics Inc, and Crispr Therapeutics AG.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tocagen Inc with a $16.30 average price target, which is a 220.9% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $14.50 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.80 and a one-year low of $4.13. Currently, Tocagen Inc has an average volume of 340.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy compan. It focuses on the development of product candidates designed to activate a patient’s immune system against their own cancer from within. It is in the business of discovery, development, and commercialization of products for the treatment of cancer.
